Neutralizing Antibodies Targeting SARS-CoV-2 Spike Protein
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for COVID-19, including drugs and vaccines, are insufficient in addressing the rapid progression of the disease and require further clinical trials, highlighting the need for effective neutralizing antibodies targeting the SARS-CoV-2 virus, particularly against the S-protein.
Innovation Solution
Development of neutralizing antibodies or antigen-binding fragments with specific complementarity determining regions (CDRs) that bind to the SARS-CoV-2 spike protein, including variants with up to two amino acid changes, and their use in pharmaceutical compositions, kits, and methods for prevention, treatment, and detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic drugs and vaccines are used for COVID-19 treatment, then clinical intervention is provided, but further clinical trials are required to confirm effectiveness and time is needed before clinical application
Solution Approach 1:
The patent performs preliminary action by developing and characterizing neutralizing antibodies against SARS-CoV-2 spike protein before widespread clinical use. The antibodies are screened, validated for neutralization activity, and prepared for clinical application in advance, reducing the time needed when clinical intervention is urgently required.
Solution Approach 2:
The patent provides beforehand cushioning by creating a portfolio of neutralizing antibodies with different characteristics (affinity, neutralization potency, epitope specificity) that can serve as backup options. This ensures that if one antibody proves insufficient in clinical trials, others are already prepared and characterized, cushioning against time losses.
2Reliability
If neutralizing antibodies are developed to bind SARS-CoV-2 spike protein, then viral neutralization is achieved, but the virus can mutate causing amino acid changes that may reduce antibody binding
Solution Approach 1:
The patent applies universality by developing antibodies that target highly conserved regions of the spike protein essential for viral function. These regions are less prone to mutation, making the antibodies effective against multiple viral variants. The patent also screens for antibodies with broad neutralization activity against different SARS-CoV-2 strains.
Solution Approach 2:
The patent uses parameter changes by modifying antibody structures (amino acid substitutions in CDR regions) to improve binding affinity and stability. The patent also evaluates antibodies under varying conditions (different variants, concentrations) to select those with optimal performance characteristics that balance neutralization efficacy with resistance to viral evolution.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively neutralize the SARS-CoV-2 virus by binding to the spike protein, providing a potential treatment and prevention method for COVID-19, with demonstrated efficacy in neutralization assays against various virus variants.
Implementation Method 1
an isolated antibody or an antigen-binding fragment comprising three complementarity determining regions (HCDRs) of a heavy chain variable region or one or more variants
Data Source
AI summary
The embodiments of the present disclosure provide an antibody or antigen-binding fragment against SARS-CoV-2 spike(S) protein, comprising: three complementarity determining regions (HCDRs) of a heavy chain variable region or one or more variants thereof, the heavy chain variable region set forth as SEQ ID NO. 30 or SEQ ID NO. 46, each of the one or more variants having at most two amino acid changes compared to the corresponding CDR; and three complementarity determining regions (LCDRs) of a light chain variable region or one or more variants thereof, the light chain variable region set forth as SEQ ID NO. 32 or SEQ ID NO. 48, each of the one or more variants having at most two amino acid changes compared to the corresponding CDR.